Efficacy and Safety of Topical Timolol Maleate 0.5% Solution for Superficial Infantile Hemangioma in Early Proliferative Phase. A Randomized Clinical Trial

Fecha de inicio: 1 de marzo de 2014

Inclusion Criteria: * Written informed consent for study participation and the use of the patient's photographs from the patient's parent(s) or guardian(s), * The patient is between 10 and 60 days of age at the time of enrollment, * The patient should have: * at least one focal or segmental hemangioma, mixed or superficial, present anywhere on the body of at least 0.3 cm of minimum diameter and not greater of 5 cm. * abortive or minimal growth hemangioma * Infantile hemangioma precursors Exclusion Criteria: * Patients \> 60 days of age * Complicated hemangiomas (life-threatening, function-threatening, or ulcerated) * Children who have previously received systemic, intra-lesional or topical corticosteroids, imiquimod, vincristine, alpha-interferon, propranolol or other beta blockers, PDL laser. * Patients with PHACES, LUMBAR, SACRAL or PELVIS syndrome. * Internal involvement hemangiomas (liver, GI tract, larynx) * Children with a personal history of asthma or cardiac conditions that may predispose to heart block. * Children with congenital birth defects * Children with Cancer (leukemia, sarcoma, neuroblastoma, retinoblastoma) * Children with a history of hypersensitivity to beta blockers or excipients.